STENTYS announced that it has commenced enrolling patients in the TRUNC trial, which is designed to evaluate the long-term safety and efficacy of the Xposition S stent in the treatment of unprotected left main coronary artery disease. TRUNC is a prospective, single-arm multi-center trial to evaluate the long-term safety and efficacy of the Xposition S stent in the treatment of unprotected left main lesions in routine clinical practice. It is scheduled to include 200 patients in approximately 20 European clinical sites. The primary endpoint is Target Lesion Failure at 12 months.